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SUMMARY
In the present study, the potential activity of two 5-nitroindazole derivatives previously proposed as suitable antichagasic
prototypeswas further evaluated ondiverseTrypanosoma cruzi strains belonging to twodiscrete typingunits (DTUs) frequently
associated with human infection (i.e. DTUs TcII and TcVI). The trypanocidal proﬁle that both 2-benzyl-1-propyl (22)
and 2-benzyl-1-butyl (24) derivatives achieved on Tulahuen amastigotes (IC50 = 3·56 ± 0·99 and 6·31 ± 1·04 µM, respect-
ively) correlates with that of formerly obtained on CL Brener, corroborating an outstanding activity on DTU TcVI para-
sites. Moreover, a sequential screening on extracellular and intracellular stages of T. cruzi Y (DTU TcII) demonstrated
also the eﬀectiveness of 22 and 24 over this strain on a similar range of activity (IC50 epimastigotes = 3·55 ± 0·47 and
7·92 ± 1·63 µM, IC50 amastigotes = 2·80 ± 0·46 and 9·02 ± 5·26 µM, respectively). These results, supported by a lack of
toxicity registered over either L929 ﬁbroblasts or primary cultures of cardiomyocytes, conﬁrm that 5-nitroindazolinones
22 and 24 display great selectivity on both drug-sensitive (CL and Tulahuen) and drug-moderately resistant (Y) T. cruzi
strains, and therefore, represent an important outcome in the research of Chagas disease chemotherapy.
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INTRODUCTION
Chagas disease (CD), caused by the kinetoplastid
haemoﬂagellate Trypanosoma cruzi, is a parasitic in-
fection naturally transmitted in 21 Latin American
countries by the contaminated feces of blood-
sucking bugs (i.e. triatomines). In the endemic
area, CD provokes more than 7000 deaths per year
and maintains over 25 million people at risk for the
infection (WHO, 2015). Moreover, its emerging
character in non-endemic areas due to population
mobility and alternative routes of transmission
(e.g. blood transfusion, organ donation, mother-to-
child and through contaminated food) (Schmunis
and Yadon, 2010) has contributed to the spreading
of an illness that currently aﬀects about 7 million
people worldwide (WHO, 2015).
As one of the 17 tropical diseases deﬁned by the
WHO as neglected (WHO, 2015), strategies of re-
search and development are focused on the ﬁnding
of a suitable CD chemotherapy (Zingales et al.
2014). Many eﬀorts have been made by institu-
tions in order to develop new compounds poten-
tially applicable to the treatment of CD, since the
available chemotherapy relies on two old nitroheter-
ocyclic drugs: benznidazole (BZ), the ﬁrst-line treat-
ment in most countries, and nifurtimox (NX)
(WHO, 2015). Although these medicines are cur-
rently accepted to treat the acute and the early-
chronic disease, both show limited eﬀectiveness
in long-term chronic infections (Urbina, 2015)
and also exhibit undesirable side eﬀects (Castro
et al. 2006).
Concerning experimental chemotherapy research,
in a previous study we proposed the 1,2-disubsti-
tuted 5-nitroindazolinone scaﬀold as prototype of
antichagasic drug (Vega et al. 2012). Concretely,
the 2-benzyl-1-propyl (22) and the 2-benzyl-1-
butyl (24) derivatives (Fig. 1) achieved outstanding
activity over the replicative stages of T. cruzi (i.e.
epimastigotes and amastigotes) without toxicity on
macrophages, what led to great selectivity on CL
Brener strain (Vega et al. 2012; Fonseca-Berzal
et al. 2014).
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Trypanosoma cruzi populations have been classiﬁed
into six discrete typing units (DTUs TcI–TcVI)
according to molecular genetics, eco-epidemiological
features and pathogenicity (Zingales et al. 2014).
Moreover, susceptibility to reference drugs also
varies among T. cruzi strains, with CL Brener
and Tulahuen (TcVI) known as drug-sensitive, Y
(TcII) as drug-moderately resistant and Colombian
(TcI) as drug-resistant strain (Soeiro et al. 2013).
In this context, the Parasitology Department of
UCM (Madrid, Spain), the Medicinal Chemistry
Institute of CSIC (Madrid, Spain) and the Cellular
Biology Laboratory of IOC/Fiocruz (Rio de Janeiro,
Brazil) have worked in collaboration to further
explore the trypanocidal spectrum of these candi-
dates, following routinely screening procedures stan-
dardized by these laboratories. Consequently, the
aimsof thepresent studywere: (i) to analyse the trypa-
nocidal proﬁle of prototypes 22 and 24 on other
T. cruzi strains belonging to DTUs involved in
human infection; (ii) to evaluate their activity in an
in vitro golden model that uses primary cultures of
cardiac cells as mammalian hosts since heart is one
of the main targets for CD infection and inﬂamma-
tion; and (iii) to conﬁrm their lack of toxicity over
diﬀerent mammalian cell cultures.
MATERIALS AND METHODS
Ethics
All procedures involving mice were carried out in
accordance with the guidelines established by the
Fiocruz Committee of Ethics for the Use of
Animals (CEUA LW16/14).
Compounds
The synthesis of the two 5-nitroindazole derivatives
assayed in the present work (Fig. 1) was previously
described (Vega et al. 2012). The numbering of
compounds used in this reference has been
followed in the present paper. For all the in vitro
assays, stock solutions of 22 and 24 were prepared
in dimethyl sulfoxide and extemporaneously added
to the cultures in a ﬁnal concentration of the
solvent non-toxic itself (<1%, v/v). BZ (Laboratório
Farmacêutico do Estado de Pernambuco – LAFEPE,
Brazil) was assayed as a reference drug.
Mammalian cell cultures
Primary cultures of embryonic cardiomyocytes
(CM) were obtained from Swiss mice as previously
described (Meirelles et al. 1986). After their puriﬁca-
tion, CM cultures were sustained in Dulbecco’s
Modiﬁed Eagle’s Medium (DMEM) supplemented
with 2·5 mM CaCl2, 1 mM L-glutamine, 5% heat-
inactivated fetal bovine serum (FBS) (30 min,
56 °C) and 2% chicken embryo extract. CM cultures
were maintained at 37 °C in a humidiﬁed atmos-
phere of 5% CO2.
Murine L929 ﬁbroblasts were grown in plastic
culture ﬂasks (75 cm2) using either Minimal Essential
Medium (MEM)without phenol-red and supplemen-
ted as reported (Fonseca-Berzal et al. 2014) (MEMS)
or RPMI-1640 without phenol-red supplemented
with 10% heat-inactivated FBS and 2 mM glutamine
(RPMIS). L929 cultures were maintained in a humi-
diﬁed 5% CO2 atmosphere at 37 °C and subpassaged
once a week. A 0·03% ethylenediaminetetraacetic acid
(EDTA) and 0·05% trypsin in phosphate-buﬀered
saline (PBS) solution was used for cell detachment.
Parasites
The Y strain of T. cruzi, originally isolated from
an acute human case (Silva and Nussenzweig, 1953)
and the Tulahuen strain, stably transfected with the
Escherichia coli β-galactosidase gene lacZ (Buckner
et al. 1996) were used throughout the experiments.
Regarding the Y strain, epimastigotes were main-
tained at 28 °C in supplemented liver infusion
tryptose (LIT) medium as described in (Vega
et al. 2012) and the axenic cultures continuously
maintained in logarithmic growth by weekly pas-
sages. Bloodstream trypomastigotes (BT) of this
strain were obtained by heart puncture from
infected Swiss mice at the parasitaemia peak day
and after their puriﬁcation, resuspended in RPMI
medium supplemented with 5% heat-inactivated
FBS.
Concerning Tulahuen parasites, tissue culture-
derived trypomastigotes (TCT) of this β-galactosi-
dase-transfected strain were harvested in the
supernatant of L929 cultures previously infected
with invasive forms of T. cruzi and maintained in
RPMIS at 37 °C in a humidiﬁed 5%CO2 atmosphere
(Romanha et al. 2010).
Epimastigote susceptibility assay
The activity on epimastigotes was evaluated by ap-
plying the resazurin assay previously standardized
by Rolón et al. (2006). Log-phase epimastigotes in
LIT medium were seeded in the culture tubes at
Fig. 1. Chemical structures of the prototypes 2-benzyl-5-
nitro-1-propylindazolin-3-one (22) and 2-benzyl-1-butyl-
5-nitroindazolin-3-one (24).
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a density of 3 × 106 parasites mL−1 and maintained
at 28 °C overnight to allow homogeneous growth.
Afterwards, cultures were distributed in 96-well
microplates (200 µL perwell) and incubated within
the compounds for 48 h at 28 °C. Growth, medium
and drug controls were also included in each assay
and concentrations tested in triplicate. Finally,
20 μL of a resazurin solution in 1% PBS (3 mM, pH
7) was added per well and the plates maintained at
28 °C for another 5 h. Fluorescence intensity was
measured with excitation (535 nm) and emission
(590 nm) wavelengths (alamarBlue® Assay, U.S.
Patent No. 5 501 959) and the results represent the
percentage of epimastigote growth inhibition (%
EGI). For each compound, the concentration that
inhibits 50% of epimastigote growth (IC50) was esti-
mated by plotting the concentrations tested vs the %
EGI. Selectivity indexes (SI) and potencies relative
to BZ (RP) were also estimated.
Cytotoxicity assays
In order to detect any potential toxicity towards the
host cell, cultures of CM and L929 were incubated
within these compounds and the metabolic cell func-
tion was measured in the presence of resazurin-based
indicators (PrestoBlue® and Resazurin sodium salt,
respectively).
According to this, 100 µL of DMEM containing
6 × 104 CM per well were seeded in 96-well micro-
plates previously coated with gelatin and incubated
overnight at 37 °C in a humidiﬁed 5% CO2 atmos-
phere. Afterwards, the medium was replaced by
solutions of each compound in fresh DMEM and
the plates were incubated either 24 or 48 h in the
conditions aforementioned. Each concentration was
evaluated in triplicate and controls of cellular
growth were included in all the plates. Once the in-
cubation concluded, both cell morphology and con-
tractibility were examined by light microscopy and
cellular viability evaluated by adding the redox indi-
cator PrestoBlue® according to the manufacturer’s
instructions. After 5 h of incubation at 37 °C in a
humidiﬁed 5% CO2 atmosphere, the absorbance
was read at 570 and 600 nm and the results were
expressed as the percentage of cytotoxicity on CM
(%CCM) (Romanha et al. 2010).
Moreover, the unspeciﬁc cytotoxicity over L929
was assayed in 96-well plates by seeding either
10 × 103 or 15 × 103 cells in 100 µL of MEM per
well. In order to allow cell attachment, the plates
were incubated for 3 h at 37 °C in a humidiﬁed 5%
CO2 atmosphere and then, the medium was replaced
by 200 µL of compounds diluted in freshMEM. Each
concentration was tested in triplicate. Growth,
medium and drug controls were also included in
each plate. Fibroblasts were exposed to the com-
pounds for 48, 72 and 96 h at 37 °C with 5% CO2.
Afterwards, 20 µL of a resazurin in 1% PBS solution
(2 mM, pH 7) was added to each well and the plates
were returned to the incubator for another 3 h.
Finally, ﬂuorescence intensity was read at 535 nm (ex-
citation) and 590 nm (emission) and the results were
expressed as %CL929 (Fonseca-Berzal et al. 2015).
For both assays, the concentration that inhibits
50% of cellular growth (LC50) was estimated by plot-
ting drug concentrations vs %C.
Intracellular amastigote susceptibility assays
The activity on intracellular amastigotes was evalu-
ated by infecting either L929 ﬁbroblasts with TCT
(Tulahuen strain) or CM with BT (Y strain) in a
10:1 ratio (parasite:cell).
For the ﬁrst bioassay, 100 µL of RPMIS containing
4000 L929 cells per well was seeded in 96-well tissue
culture plates and maintained for 24 h at 37 °C in a
humidiﬁed 5% CO2 atmosphere. Afterwards, cells
were incubated within TCT for another 2 h and
then, non-penetrated parasites were discarded re-
placing the culture medium by fresh RPMIS. In
order to establish the infection, the plates were main-
tained during 48 h at 37 °C and 5% CO2 and then, the
medium was replaced by solutions of each compound
in fresh RPMIS. Each concentration was evaluated in
triplicate. Controls of infection and cell growth were
also included and the plates were incubated for 96 h
at the same conditions of temperature and humidity.
After this period, 50 µL of 500 µM chlorophenol red
glycoside in 0·5% Nonidet P40 was added to each
well and the plates were incubated for 18 h at 37 °C.
Finally, the absorbance was read at 570 nm and the
results were expressed as the percentage of amastigote
growth inhibition (%AGI) (Romanha et al. 2010).
To assay these compounds over Y strain amasti-
gotes, 100 000 CM per well were seeded in 24-well
tissue culture plates provided with round coverslips
previously coated with gelatin and then, maintained
in DMEM overnight at 37 °C in a humidiﬁed 5%
CO2 atmosphere. After 24 h of parasite–host cell
interaction, the infected cultures were washed to
remove non-internalized trypomastigotes and then,
incubated for another 48 h within the compounds
diluted in fresh DMEM. Next, the cultures were
ﬁxed with Bouin’s ﬁxative and stained with
Giemsa. The mean number of infected CM and
the mean number of parasites per infected CM
were scored in 400 host cells by duplicate. Only
parasites with characteristic nuclei and kinetoplast
were counted, since the irregular ones were consid-
ered as parasites undergoing death. Finally, activity
results were estimated by calculating the inhibition
of the endocytic index (EI) (da Silva et al. 2007).
In each assay, compounds IC50 and IC90 (concen-
tration that inhibits 50 and 90% of amastigote prolif-
eration or EI, respectively) were estimated by
plotting concentrations vs %AGI or %EI. SI over
the respective host cell and RP were also calculated.
35-nitroindazolinones eﬀect in vitro on T. cruzi models
All the in vitro assays were run in the same condi-
tions at least twice separately. For each assay, the
results are expressed as the mean value of activity
± standard deviation (S.D.).
Statistical analysis
SPSS Statistics software (version 20, IBM) was
used for the statistical analysis. The non-parametric
Kruskal–Wallis test was applied to compare com-
pounds activity between the diﬀerent strains, as
well as with that of BZ. P< 0·05 was considered stat-
istically signiﬁcant.
RESULTS
Toxicity on mammalian host cells
Since both CM and L929 were used as T. cruzi host
cell, thepotential toxicityof22and24over thesemam-
malian cells was assessed in vitro. As Fig. 2 reﬂects, no
toxicity was perceived on the treated CM, and there-
fore, percentages of cell viability greater than 85%
were registered in all the cases. In fact, bothderivatives
achieved LC50 values higher than 100 µM after the in-
cubation times assayed (i.e. 24 and 48 h). Moreover,
the light microscopy analysis revealed neither alter-
ation in cell morphology nor aﬀectation in contract-
ibility as a treatment consequence.
Nevertheless, both compounds achieved a diﬀerent
cytotoxic proﬁle on L929 ﬁbroblasts. After 48 h of
drug–cell contact, concentrations higher than 33·3
µM led to a pronounced loss of cellular viability that
varied in a time-dependent manner. Likewise, BZ
induced higher toxicity on this mammalian cell line,
showing a response similar to that of derivative 22
(Fig. 3 and Table 1). However, at the highest con-
centration tested and after completing the three
incubation times assayed on L929, no diﬀerences
were detected between the toxic proﬁle of 5-nitroin-
dazolinones and BZ (P > 0·05).
Activity on epimastigotes (Y strain)
As a primary screening, the inhibitory eﬀect of deri-
vatives 22 and 24 was evaluated on axenic cultures
of epimastigotes. Both compounds displayed a
better trypanocidal proﬁle compared with that of
Fig. 2. Toxic eﬀect of the 5-nitroindazolinones over primary cultures of CM after 24 h (A) and 48 h (B) of treatment.
Fig. 3. Toxic eﬀect of the 5-nitroindazolinones over L929 cells after 48 h (A), 72 h (B) and 96 h (C) of treatment.
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BZ (Fig. 4). They obtained improved IC50 values and
remarkable SI on the extracellular parasite (Table 2),
signiﬁcantly better in the case of derivative 22 (P<
0·05). Otherwise, the potency of these molecules
could not be determined at this level, since their
IC90 were reached at concentrations superior than
the highest one assayed.
Activity on intracellular amastigotes
The inhibitory eﬀect of 22 and 24 was further eval-
uated over Tulahuen and Y strain amastigotes
grown in L929 and CM cultures, respectively.
According to the results of cytotoxicity (Table 1),
concentrations higher than 50 µM were not tested at
this level. Although both compounds displayed
slightly lower dose–response curves upon Tulahuen
parasites compared with that of BZ (Fig. 5 and
Table 3), they reached outstanding SI on the intracel-
lular stage and were as potent (P> 0·05) as the refer-
ence drug (Table 3).
Regarding the activity upon Y strain amastigotes,
although compound 22 achieved similar IC50 values
for both the strains (P > 0·05), it accomplished a
better IC90 after a 2-day treatment of Y-infected
cells and a nearly suppression of the EI at 25 µM
(%EI = 99·43 ± 0·32%) (Fig. 6), showing a trypano-
cidal proﬁle similar to that of BZ (Table 4).
Otherwise, derivative 24 was not only less eﬀective
but also with lower potency on this latter strain
(Table 4). However, at 25 µM it obtained a consider-
able reduction in both the percentage of infected
cells and the mean number of amastigotes per
infected cell, as the inhibition in the EI reﬂects
(%EI ca. 71%) (Figs 6 and 7).
DISCUSSION
The selection of diverse T. cruzi strains and clones
for in vitro drug screening is an important point to
consider in the early research of putative candidates
for CD chemotherapy (Zingales et al. 2014). In fact,
the diﬀerent eﬀectiveness that BZ and NX display
among divergent strains is one of the aspects
on which the current Chagas therapy failure
resides (Urbina, 2015). Although a clear correlation
between T. cruzi genetic variability and its presum-
able response to drugs has not been evidenced
(Moraes et al. 2014), strategies for drug screening
Table 1. Toxic eﬀect of derivatives 22 and 24 on L929 cells
Compound
48 h 72 h 96 h
%Ca LC50 (μM)
b %C LC50 (μM) %C LC50 (μM)
22 22·74 ± 17·74 >100 30·70 ± 9·98 >100 52·66 ± 12·34 86·57 ± 10·77
24 60·97 ± 3·94 79·79 ± 4·64 63·59 ± 4·26 67·44 ± 5·48 77·39 ± 1·75 55·34 ± 7·89
BZ 35·13 ± 14·33 >100 35·17 ± 3·27 >100 43·52 ± 2·79 >100
* Signiﬁcant diﬀerences (P < 0·05) compared with BZ (Kruskal–Wallis test).
a Results expressed as the mean value of cytotoxicity (%C) at the highest concentration tested (100 µM) ± standard devi-
ation (S.D.) of three independent experiments (n= 3).
b The concentration causing 50% of cellular lethality (LC50) was estimated by plotting drug concentrations vs %C. The
results are expressed as the mean ± S.D. of three independent experiments (n= 3).
Fig. 4. Dose–response curves of 22 (A), 24 (B) and BZ (C)
on epimastigotes (Y strain).
55-nitroindazolinones eﬀect in vitro on T. cruzi models
should focus its performance on parasite DTUs
more often associated with human infection
(DTUs TcI, TcII, TcV and TcVI) (Zingales et al.
2014).
In previous studies, indazole-based compounds
have demonstrated great eﬀectiveness on diﬀerent
T. cruzi strains (reviewed in Aguilera-Venegas
et al. 2013). Concretely, several series of 5-nitroinda-
zole derivatives have achieved important outcomes
exhibiting notable anti-T. cruzi activity (Arán et al.
2005; Boiani et al. 2009; Vega et al. 2012; Muro
et al. 2014), being some of these molecules proposed
to trigger reactive oxygen species (ROS)-based
mechanisms of action (Folch-Cano et al. 2010).
In this framework, we have formerly identiﬁed the
5-nitroindazolinones 22 and 24 as promising antic-
hagasic candidates, since the great activity they
achieved on epimastigotes (IC50 = 0·93 and 1·17
µM, respectively) and intracellular amastigotes
(IC50 < 1 and 3·71 µM, respectively) of T. cruzi CL
Brener (Vega et al. 2012; Fonseca-Berzal et al.
2014). The results of this primary screening on a
β-galactosidase-transfected clone (Buckner et al.
1996) with a biological behaviour similar to that of
the parental CL strain (TcVI) (Le-Senne et al.
2002), prompted us to perform a deeper study of
their broad activity on other T. cruzi strains
(Zingales et al. 2014). Consequently, further screen-
ing procedures were carried out on intracellular
forms of Tulahuen strain to conﬁrm their activity
on TcVI parasites, as well as over both extracellular
and intracellular stages of T. cruzi Y, representative
strain of TcII.
Moreover, an analysis of compounds relative
cytotoxicity was simultaneously conducted.
Although both candidates did not exert any toxic
eﬀect on J774 macrophages after 24 h of drug expos-
ure (Vega et al. 2012), it is important to verify this
fact over those mammalian cells hosting the parasite
in subsequent trypanocidal assays (Fonseca-Berzal
et al. 2014). In addition, either CM or ﬁbroblasts
are preferred as host cell for such an experimental
model, since both are T. cruzi target cells more
strictly involved in the pathology of the disease and
only some parasite isolates concentrate infection in
the mononuclear phagocytic system (Teixeira et al.
2006). Moreover, heart is an important target for in-
fection and inﬂammation in CD pathology and
Table 2. Trypanocidal activity of 22 and 24 on Y strain epimastigotes expressed as IC50, IC90 and SI
Compound IC50 (μM)
a IC90 (μM) LC50 CM (μM)
b SIc
22 3·55 ± 0·47*,** >32 >100 >28·17
24 7·92 ± 1·63** >32 >100 >12·62
BZ 28·00 ± 4·64 >256 >100 >3·57
* Signiﬁcant diﬀerences (P< 0·05) compared with BZ (Kruskal–Wallis test).
** Signiﬁcant diﬀerences (P < 0·05) compared with the activity on CL-B5 epimastigotes (see Vega et al. 2012) (Kruskal–
Wallis test).
a The concentration causing 50 and 90% of EGI (IC50 and IC90, respectively) was estimated by plotting drug concentra-
tions vs %EGI. The results are expressed as the mean ± S.D. of three independent experiments (n= 3).
b After 48 h of drug treatment.
c Selectivity indexes are deﬁned as SI = LC50 (48 h CM cells)/IC50 Y epimastigotes.
Fig. 5. Dose–response curves of 22 (A), 24 (B) and BZ (C)
on intracellular amastigotes (Tulahuen strain) grown in
L929 cultures.
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then, pre-clinical studies using these cells are desir-
able to exclude potential drug candidates with cardi-
otoxicity characteristics (da Silva et al. 2007).
According to this, we tested compounds 22 and 24
over uninfected L929 ﬁbroblasts and primary cul-
tures of CM in order to rule out the toxic eﬀects.
Neither compound 22 nor 24 resulted in toxicity on
CM after completing 48 h of incubation (Fig. 2).
Otherwise, high concentrations of both derivatives
seemed to induce a loss of L929 viability that
increased in a time-dependent manner, showing a be-
haviour similar to that of BZ (P> 0·05) (Fig. 3 and
Table 1). It could happen as a result of the diﬀerent
nature of both mammalian cell cultures (i.e. primary
cultures and continuous cell line, respectively)
(Duran-Rehbein et al. 2014), having obtained a
similar pattern with the reference drug (Figs 2 and
3). In fact, diﬀerences related to susceptibility and
sensitivity using the same drug have been also
reported according to the mammalian cell type and
the respective viability assay employed (Zwolak,
2014; Emter and Natsch, 2015; Xu et al. 2015).
Herein, the noticed diﬀerences in drug sensitivity
detected among ﬁbroblasts and cardiac cells may
arise due to the diﬀerent cytotoxic assays performed
(Resazurin sodium salt × PrestoBlue®) and from the
dissimilar impact susceptibility of each target cell
(ﬁbroblasts vs cardiac cells).
Several studies have reported no apparent DTU
association regarding epimastigote susceptibility to
both reference drugs (Boiani et al. 2006; Moreno
et al. 2010; Zingales et al. 2014) agreeing this
statement with the results we achieved with BZ on
CL-B5 (IC50 = 27·32 µM) (Vega et al. 2012) and Y
strain (IC50 = 28·00 µM) (P> 0·05). The variation
in glutathione content (free or mostly conjugated
as trypanothione) found among T. cruzi strains
has been also proposed as an explanation of their
diﬀerent susceptibility to both NX and BZ (Repetto
et al. 1996), since these reduced thiols play an import-
ant role in the free radical detoxiﬁcation mechanisms
of trypanosomatids (Irigoin et al. 2008). Moreover,
no relevant diﬀerences in glutathione content were
formerly established among Tulahuen, CL and Y
epimastigotes (Moncada et al. 1989) presuming a
comparable response of these strains to BZ, what
Table 3. Trypanocidal activity of 22 and 24 on intracellular amastigotes of Tulahuen strain expressed as IC50,
IC90 and SI. Compounds RP were also estimated
Compound IC50 (μM)
a IC90 (μM) LC50 L929 (μM)
b SIc RPd
22 3·56 ± 0·99 9·60 ± 1·17 86·57 ± 10·77 24·32 1·00
24 6·31 ± 1·04* 15·55 ± 4·86 55·34 ± 7·89 8·77 0·62
BZ 1·66 ± 0·10 9·63 ± 0·37 >100 >60·24 –
* Signiﬁcant diﬀerences (P< 0·05) compared with BZ (Kruskal–Wallis test).
** Signiﬁcant diﬀerences (P< 0·05) compared with the activity on CL-B5 amastigotes (see Fonseca-Berzal et al. 2014)
(Kruskal–Wallis test).
a The concentration causing 50 and 90% of amastigote growth inhibition (IC50 and IC90, respectively)was estimated by plot-
ting drug concentrations vs %AGI. The results are expressed as the mean ± S.D. of three independent experiments (n= 3).
b After 96 h of drug treatment (see Table 1).
c Selectivity indexes are deﬁned as SI = LC50 (96 h L929 cells)/IC50 Tulahuen amastigotes.
d Relative potencies are deﬁned as RP = IC90 BZ/IC90 tested compound.
Fig. 6. Dose–responsecurvesof22 (A), 24 (B) andBZ(C)on
intracellular amastigotes (Y strain) grown in CM cultures.
75-nitroindazolinones eﬀect in vitro on T. cruzi models
correlates with the similar proﬁles herein obtained
(Table 2). Although the epimastigote is not the clin-
ically relevant form of T. cruzi, the easy maintenance
this model oﬀers (Muelas et al. 2001) and the identiﬁ-
cation of an intracellular epimastigote-like form as
intermediate stage within the mammalian host
(Faucher et al. 1995), support the performance of
pre-screening models on this stage of T. cruzi.
Additionally, a correlation between both the activity
on epimastigotes and amastigotes occurs (Vega et al.
2012; Fonseca-Berzal et al. 2014). However, com-
pounds IC50 on these both stages usually diﬀer in
several orders of magnitude (Moreno et al. 2010).
Undoubtedly, posterior inhibition assays on infective
forms (i.e. trypomastigotes and amastigotes) must be
carried out in vitro before advancing compounds to in
vivo assays (Romanha et al. 2010), since diﬀerent drug
susceptibility can be registered among diﬀerent stages
from the same T. cruzi stock (Moraes et al. 2014).
According to these facts, we evaluated the eﬀec-
tiveness of derivatives 22 and 24 upon the three
main forms of T. cruzi Y strain, which is routinely
used in our laboratories for in vitro and in vivo
drug screening models (Castillo-Garit, et al. 2012;
da Silva et al. 2012; Araújo et al. 2014; Fonseca-
Berzal et al. 2015). The trypanocidal proﬁle both pro-
totypes accomplished on this strain was quite similar
to that of over CL-B5 parasites (Vega et al. 2012;
Fonseca-Berzal et al. 2014). However, our com-
pounds displayed lower activity towards epimasti-
gotes of Y strain (P< 0·05), unlike BZ (Table 2).
This fact may be connected with the moderately
Table 4. Trypanocidal activity of 22 and 24 on intracellular amastigotes of Y strain expressed as IC50, IC90
and SI. Compounds RP were also estimated
Compound IC50 (μM)
a IC90 (μM) LC50 CM (μM)
b SIc RPd
22 2·80 ± 0·46 6·02 ± 0·30 >100 >35·71 1·07
24 9·02 ± 5·26 >25 >100 >11·08 <0·25
BZ 1·77 ± 1·11 6·46 ± 1·34 >100 >56·50 –
* Signiﬁcant diﬀerences (P< 0·05) compared with BZ (Kruskal–Wallis test).
** Signiﬁcant diﬀerences (P< 0·05) compared with the activity on CL-B5 (see Fonseca-Berzal et al. 2014) and Tulahuen
amastigotes (Kruskal–Wallis test).
a The concentration causing 50 and 90% of EI inhibition (IC50 and IC90, respectively) was estimated by plotting drug
concentrations vs %EI. The results are expressed as the mean ±S.D. of two independent experiments (n= 2).
b After 48 h of drug treatment.
c Selectivity indexes are deﬁned as SI = LC50 (48 h CM cells)/IC50 Y amastigotes.
d Relative potencies are deﬁned as RP = IC90 BZ/IC90 tested compound.
Fig. 7. Light microscopy analysis of CM infected with Y strain and treated for 48 h with 6·25 µM (B), 12·50 µM (C) and
25 µM (D) of derivative 24, as well as untreated cells (A). The black arrows indicate intracellular amastigotes.
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resistance to nitroderivative drugs attributed to
T. cruzi Y (Romanha et al. 2010), contrasting with
the susceptible CL Brener (Le-Senne et al. 2002).
Moreover, 22 and 24 seemed to be more selective
than BZ on extracellular epimastigotes (SI22 >
28·17, SI24 > 12·62 and SIBZ > 3·57), since they got
better eﬀectiveness on this stage too (Table 2).
Following the criteria proposed by DNDi (Don
and Ioset, 2014), compounds that obtain IC50
values inferior than 10 µM on intracellular amasti-
gotes of TcVI or TcII are identiﬁed as putative
hits for CD chemotherapy, likewise our two deriva-
tives. These compounds formerly displayed such
an outstanding activity on CL-B5 (Fonseca-Berzal
et al. 2014) now conﬁrmed in the phenotypic assay
on Tulahuen (P> 0·05) (Table 3), both TcVI
strains. Besides, derivatives 22 and 24 also fulﬁlled
it over Y amastigotes (TcII) grown in cardiac cells
in vitro (Table 4). In fact, both compounds proved
to be 10-fold more active on the Y strain than toxic
to mammalian cells (Don and Ioset, 2014), success-
fully overpassing this preliminary hit stage (SI22 >
35·71 and SI24 > 11·08).
Nevertheless, both nitroheterocycles not only
displayed great activity on T. cruzi models, but
also were considered as suitable templates for the
design of novel anti-Trypanosoma brucei agents
(Arán et al. 2012). However, the activity they
achieved against blood trypomastigotes of both
African (Arán et al. 2012) and American trypano-
somes (data not shown) was lower than the obtained
on the multiplying stages of T. cruzi. In the present
study, our compounds achieved an improved trypa-
nocidal proﬁle on intracellular TcII parasites, like-
wise BZ (Tables 2 and 4). The activity displayed
by the reference drug on T. cruzi Y, could be again
related to variations in thiol concentration among
diﬀerent stages of a unique strain (Maya et al.
1997). According to this, the higher the content of
reduced thiols (i.e. epimastigotes > trypomastigotes
> amastigotes), the less susceptible to BZ (IC50
value on epimastigotes > trypomastigotes > amasti-
gotes). Actually, in a previous in vivo study we
found that 22 and 24 did not entirely suppress para-
sitaemia through the acute disease in mice, but
obtained a considerably reduction in BT levels after
concluding a 5-day treatment (Fonseca-Berzal et al.
2014). The activity on BT was higher for derivative
24 either in vivo (Fonseca-Berzal et al. 2014) or in
vitro models (data not shown), which conversely
was the less active derivative on intracellularT. cruzi.
Theresults compiled in thepresent studycorroborate
these two 5-nitroindazolinone derivatives as putative
antichagasic prototypes. Both compounds bore out re-
markable eﬀectiveness on the clinically relevant stage
of TcII and TcVI strains with a lack of toxicity on
diverse host cells that resulted in great selectivity on
T. cruzi. Concretely, the 2-benzyl-5-nitro-1-propylin-
dazolin-3-one (22) showed trypanocidal and cytotoxic
proﬁles similar to those of the reference drug BZ.
Further investigation directed to explore the mechan-
ism of action triggered by these compounds is currently
underway.
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